Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
Naše společnostiAktuálněInsights

O skupině PPF

O násLidé a statutární orgányFinanční výsledky a výkazyZprávy a dokumenty

Společenská odpovědnost

Společenská odpovědnostUdržitelnost
Pro médiaKontaktyKariéra
en

Novinky do e-mailu

Nechte si zasílat nejnovější tiskové zprávy, rozhovory, podcasty a insighty

Odebírat novinky

Sledujte nás

Pro média

  • Tiskové zprávy
  • Rozhovory a podcasty
  • Odebírat novinky
  • Ke stažení
  • Kontakt pro média

Může se hodit

  • Naše společnosti
  • Aktuálně
  • Insights

Kontakty

  • Společnosti skupiny PPF
  • Podmínky používání
  • Ochrana osobních údajů
  • Mapa stránek
  • Cookies policy

2026 © PPF Group

Nejčastěji hledáte

Výroční zprávyInsightsVize a strategieTiskové zprávy

  • Insights

  • Biotech Market / Business Intelligence

  • February 2025 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

Trump demands pharmas provide “most favored nation pricing” for Medicaid drugs

SOTIO Biotech

19/8/2025 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

The FDA's top vaccine official, Vinay Prasad, has left the agency after just three months as Director of CBER. President Trump demands pharmas provide “most favored nation” pricing for Medicaid drugs, prices that are lower than those in other developed countries. NBI added 5 % during July.

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz

Podobné články

SOTIO Biotech

15/8/2025

Legal Notice 5/2025

SOTIO Biotech

2/4/2025

First rounds of FDA layoffs led by the new Health Secretary form uncertain environment

SOTIO Biotech

2/4/2025

Odronextamab BLA accepted for FDA review for the treatment of follicular lymphoma

SOTIO Biotech

2/4/2025

Cargo Therapeutics discontinued its CAR-T treatment firi-cel in Phase 2 study of firi-cel

SOTIO Biotech

2/4/2025

FDA approved Adcetris for treatment of patients with large B-cell lymphoma

SOTIO Biotech

2/4/2025

ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC

SOTIO Biotech

2/4/2025

Legal Notice

Insights

Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI)

NBI trend

Area

Company

Ticker

Price range $

Δ  Price

MktCap $m

Δ MktCap $m

ADC

ADC Therapeutics

ADCT

2.67 – 3.35

3

%

274

9

Elevation Oncology

ELEV

0.36 – 0.39

-2

%

21

0

Mersana Therapeutics

MRSN

6.75 – 10.14

-7

%

854

-69

Sutro Biopharma

STRO

0.68 – 0.92

13

%

67

8

IL15 / 2

ImmunityBio

IBRX

2.46 – 3.01

-7

%

2 100

-154

Mural Oncology

MURA

2.25 – 2.58

-9

%

39

-4

Nektar Therapeutics

NKTR

21.68 – 26.67

-16

%

269

-52

Werewolf Therapeutics

HOWL

1.05 – 1.41

11

%

54

5

CAR-T

Allogene Therapeutics

ALLO

1.16 – 1.66

9

%

267

22

Arcellx

ACLX

64.69 – 71.54

8

%

3 922

304

Autolus Therapeutics

AUTL

2.26 – 2.68

5

%

639

32

Mustang Bio

MBIO

1.19 – 3.34

60

%

7

3

Other

Arcus Biosciences

RCUS

8.22 – 10.23

12

%

966

105

Immutep

IMMP

1.63 – 1.80

6

%

253

15

MacroGenics

MGNX

1.26 – 1.81

29

%

98

22

ADC Therapeutics 

ADCT announced that it has made grants of options to purchase an aggregate of 17,000 of the company's common shares to one new employee on July 1, 2025.

Elevation Oncology 

Elevation Oncology announced the completion of its merger with Concentra Biosciences. The company, with a market capitalization of approximately $21.6 million, has maintained a strong liquidity position. The ELEV stock was delisted from Nasdaq. 

Mersana Therapeutics 

Mersana announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company’s common stock. One of the primary goals of the split is to increase the per-share market price of the company’s common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on Nasdaq.

Sutro Biopharma 

Sutro has entered into a collaboration with FDA to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug development. The collaboration will leverage Sutro’s cell-free XpressCF technology to precisely engineer ADCs with predefined attributes, as well as FDA’s cutting-edge analytical capabilities to fully characterize these materials.

ImmunityBio 

ImmunityBio has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants, that is expected to result in gross proceeds at closing of approximately $80 million. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million.

Mural Oncology 

Short interest of Mural increased by 9 % to 232,683 reported on July 15, compared to 212,773 on June 13.

Nektar Therapeutic 

Nektar announced positive results from its mid-stage REZOLVE-AD study for rezpegaldesleukin, which is an eczema treatment. The Phase 2b REZOLVE-AD study evaluated rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis, who had not previously received biologic or JAK inhibitor therapies. Patients received 3 under-the-skin injections of the drug. After 16 weeks, patients showed improvements in symptoms as measured by the Eczema Area and Severity Index/EASI. 

Werewolf Therapeutics 

Werewolf announced its CMO, Randi Isaacs, attended as a speaker at the KidneyCAN 7th Annual Kidney Cancer Research Summit taking place in Boston.

Allogene Therapeutics 

Short interest of Allogene dropped by 6 % to 25,930,643 reported on July 15, compared to 27,361,306 on May 13.

Autolus Therapeutics 

Autolus announced that the EC has granted marketing authorization for Aucatzyl (obe-cel) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The EC approval was based on the results of the FELIX study. The Complete Response/Complete Response with Incomplete Hematological Recovery (CR/CRi) for patients who received at least one infusion of obe-cel was 76.6%. Median response duration for all infused patients was 21.2 months. Median event-free survival (EFS) was 11.9 months and the estimated 6- and 12-month event-free survival rates were 65.4% and 49.5%, respectively.

Arcellx 

Short interest of Arcellx dropped by 5 % to 6,020,953 reported on July 15, compared to 6,241,013 on June 13.

Mustang Bio 

Mustang announced that FDA has granted Orphan Drug Designation to Mustang for MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of recurrent diffuse and anaplastic astrocytoma and glioblastoma.

Arcus Biosciences 

Arcus announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted Orphan Drug designation by FDA for the treatment of pancreatic cancer.

Immutep 

Immutep announced an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase 3 trial at the IASLC 2025 World Conference on Lung Cancer (WCLC). The trial is evaluating efti in combination with Keytruda and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer.

MacroGenics 

Short interest of MacroGenics dropped by 26 % to 4,075,313 reported on July 15, compared to 5,534,792 on June 13.